文献速递性腺与生殖内分泌垂体与肾上腺疾病

MC3R有害变异在体质性生长和青春期延迟患者中的患病率

Prevalence of Deleterious Variants in MC3R in Patients With Constitutional Delay of Growth and Puberty.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

研究检测362例体质性生长和青春期延迟(CDGP)患者、657例嗅觉正常的特发性低促性腺激素性性腺功能减退症(nIHH)患者及5774名人群对照的MC3R序列,发现MC3R功能丧失变异在CDGP中占比2.2%(8/362,OR=4.17,P=.001),在nIHH中无强烈过表达证据(4/657,0.6%,OR=1.15,P=.779);英国生物银行246328名女性中,预测有害变异与自报月经初潮延迟(≥16岁)相关(OR=1.66,P=3.90E-07)。

要点

  • MC3R功能丧失变异在CDGP患者中占2.2%(8/362),OR=4.17,P=.001。
  • nIHH患者中MC3R功能丧失变异占0.6%(4/657),OR=1.15,P=.779。
  • 英国生物银行女性中预测有害变异与初潮延迟相关,OR=1.66,P=3.90E-07。

核心结论

  • MC3R功能损害性变异在CDGP个体中过表达,但不是该表型的常见原因。

研究设计与样本

  • 检测362例临床诊断CDGP青少年、657例nIHH患者及5774名人群对照的MC3R序列,并对所有非同义变异进行信号传导特性实验表征。
  • 在英国生物银行队列中分析自报月经初潮/变声延迟与正常个体的预测有害变异相对频率。

主要发现

  • CDGP患者中MC3R功能丧失变异8/362(2.2%),OR=4.17,P=.001。
  • nIHH患者中MC3R功能丧失变异4/657(0.6%),OR=1.15,P=.779,无强烈过表达证据。
  • 英国生物银行246328名女性中,预测有害变异在自报月经初潮延迟(≥16岁)者中更常见,OR=1.66,P=3.90E-07。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The melanocortin 3 receptor (MC3R) has recently emerged as a critical regulator of pubertal timing, linear growth, and the acquisition of lean mass in humans and mice. In population-based studies, heterozygous carriers of deleterious variants in MC3R report a later onset of puberty than noncarriers. However, the frequency of such variants in patients who present with clinical disorders of pubertal development is currently unknown. OBJECTIVE: This work aimed to determine whether deleterious MC3R variants are more frequently found in patients clinically presenting with constitutional delay of growth and puberty (CDGP) or normosmic idiopathic hypogonadotropic hypogonadism (nIHH). METHODS: We examined the sequence of MC3R in 362 adolescents with a clinical diagnosis of CDGP and 657 patients with nIHH, experimentally characterized the signaling properties of all nonsynonymous variants found and compared their frequency to that in 5774 controls from a population-based cohort. Additionally, we established the relative frequency of predicted deleterious variants in individuals with self-reported delayed vs normally timed menarche/voice-breaking in the UK Biobank cohort. RESULTS: MC3R loss-of-function variants were infrequent but overrepresented in patients with CDGP (8/362 [2.2%]; OR = 4.17; P = .001). There was no strong evidence of overrepresentation in patients with nIHH (4/657 [0.6%]; OR = 1.15; P = .779). In 246 328 women from the UK Biobank, predicted deleterious variants were more frequently found in those self-reporting delayed (aged ≥16 years) vs normal age at menarche (OR = 1.66; P = 3.90E-07). CONCLUSION: We have found evidence that functionally damaging variants in MC3R are overrepresented in individuals with CDGP but are not a common cause of this phenotype.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Duckett K, Williamson A, Kincaid JWR, et al. Prevalence of Deleterious Variants in MC3R in Patients With Constitutional Delay of Growth and Puberty. J Clin Endocrinol Metab. 2023. PMID: 37339320. doi:10.1210/clinem/dgad373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。